Restenosis trial to begin in October:
This article was originally published in Clinica
Executive Summary
Spectranetics has said it hopes to begin its in-stent restenosis clinical trial in October and has appointed Duke Clinical Research Institute as the trial co-ordination centre. The trial will assess Spectranetics' CVX-300 excimer laser coronary angioplasty system with angioplasty versus angioplasty alone on patients with blocked stents (see Clinica No 842, p 17).